176 related articles for article (PubMed ID: 29040012)
1. Outcome of acute lymphoblastic leukemia in children with down syndrome-Polish pediatric leukemia and lymphoma study group report.
Zawitkowska J; Odój T; Drabko K; Zaucha-Prażmo A; Rudnicka J; Romiszewski M; Matysiak M; Kwiecińska K; Ćwiklińska M; Balwierz W; Owoc-Lempach J; Derwich K; Wachowiak J; Niedźwiecki M; Adamkiewicz-Drożyńska E; Trelińska J; Młynarski W; Kołtan A; Wysocki M; Tomaszewska R; Szczepański T; Płonowski M; Krawczuk-Rybak M; Ociepa T; Urasiński T; Mizia-Malarz A; Sobol-Milejska G; Karolczyk G; Kowalczyk J
Pediatr Hematol Oncol; 2017 May; 34(4):199-205. PubMed ID: 29040012
[TBL] [Abstract][Full Text] [Related]
2. Outcome and toxicity of chemotherapy for acute lymphoblastic leukemia in children with Down syndrome.
Shah N; Al-Ahmari A; Al-Yamani A; Dupuis L; Stephens D; Hitzler J
Pediatr Blood Cancer; 2009 Jan; 52(1):14-9. PubMed ID: 18802938
[TBL] [Abstract][Full Text] [Related]
3. Outcome of children and adolescents with Down syndrome treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols 00-001 and 05-001.
Athale UH; Puligandla M; Stevenson KE; Asselin B; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Sulis ML; Welch JJG; Harris MH; Neuberg DS; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2018 Oct; 65(10):e27256. PubMed ID: 29878490
[TBL] [Abstract][Full Text] [Related]
4. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
5. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
6. Acute lymphoblastic leukemia in children with Down syndrome: Comparative analysis versus patients without Down syndrome.
Pennella CL; Rossi JG; Baialardo EM; Alonso CN; Guitter MR; Sánchez La Rosa CG; Millán NC; Alfaro EM; Zubizarreta PA; Felice MS
Arch Argent Pediatr; 2018 Aug; 116(4):e500-e507. PubMed ID: 30016023
[TBL] [Abstract][Full Text] [Related]
7. Acute lymphoblastic leukemia and Down syndrome: presenting features and treatment outcome in the experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP).
Arico M; Ziino O; Valsecchi MG; Cazzaniga G; Baronci C; Messina C; Pession A; Santoro N; Basso G; Conter V;
Cancer; 2008 Aug; 113(3):515-21. PubMed ID: 18521927
[TBL] [Abstract][Full Text] [Related]
8. Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children's Oncology Group.
Matloub Y; Rabin KR; Ji L; Devidas M; Hitzler J; Xu X; Bostrom BC; Stork LC; Winick N; Gastier-Foster JM; Heerema NA; Stonerock E; Carroll WL; Hunger SP; Gaynon PS
Blood Adv; 2019 Jun; 3(11):1647-1656. PubMed ID: 31160295
[TBL] [Abstract][Full Text] [Related]
9. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
[TBL] [Abstract][Full Text] [Related]
10. Long-term prognosis of children with Down's syndrome and leukaemia: a 34-year nation-wide experience.
Rajantie J; Siimes MA
J Intellect Disabil Res; 2003 Nov; 47(Pt 8):617-21. PubMed ID: 14641809
[TBL] [Abstract][Full Text] [Related]
11. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.
Creutzig U; Reinhardt D; Diekamp S; Dworzak M; Stary J; Zimmermann M
Leukemia; 2005 Aug; 19(8):1355-60. PubMed ID: 15920490
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of patients with Down syndrome and acute leukemia: A retrospective observational study.
Schmidt MP; Colita A; Ivanov AV; Coriu D; Miron IC
Medicine (Baltimore); 2021 Oct; 100(40):e27459. PubMed ID: 34622870
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome.
Meyr F; Escherich G; Mann G; Klingebiel T; Kulozik A; Rossig C; Schrappe M; Henze G; von Stackelberg A; Hitzler J
Br J Haematol; 2013 Jul; 162(1):98-106. PubMed ID: 23594030
[TBL] [Abstract][Full Text] [Related]
14. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group.
Buitenkamp TD; Izraeli S; Zimmermann M; Forestier E; Heerema NA; van den Heuvel-Eibrink MM; Pieters R; Korbijn CM; Silverman LB; Schmiegelow K; Liang DC; Horibe K; Arico M; Biondi A; Basso G; Rabin KR; Schrappe M; Cario G; Mann G; Morak M; Panzer-Grümayer R; Mondelaers V; Lammens T; Cavé H; Stark B; Ganmore I; Moorman AV; Vora A; Hunger SP; Pui CH; Mullighan CG; Manabe A; Escherich G; Kowalczyk JR; Whitlock JA; Zwaan CM
Blood; 2014 Jan; 123(1):70-7. PubMed ID: 24222333
[TBL] [Abstract][Full Text] [Related]
15. Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment.
Chessells JM; Harrison G; Richards SM; Bailey CC; Hill FG; Gibson BE; Hann IM
Arch Dis Child; 2001 Oct; 85(4):321-5. PubMed ID: 11567943
[TBL] [Abstract][Full Text] [Related]
16. Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study.
Taga T; Shimomura Y; Horikoshi Y; Ogawa A; Itoh M; Okada M; Ueyama J; Higa T; Watanabe A; Kanegane H; Iwai A; Saiwakawa Y; Kogawa K; Yamanaka J; Tsurusawa M
Pediatr Blood Cancer; 2011 Jul; 57(1):36-40. PubMed ID: 21557456
[TBL] [Abstract][Full Text] [Related]
17. Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol.
Patrick K; Wade R; Goulden N; Rowntree C; Hough R; Moorman AV; Mitchell CD; Vora A
Br J Haematol; 2014 May; 165(4):552-5. PubMed ID: 24428704
[TBL] [Abstract][Full Text] [Related]
18. Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Münster Group.
Dördelmann M; Schrappe M; Reiter A; Zimmermann M; Graf N; Schott G; Lampert F; Harbott J; Niemeyer C; Ritter J; Dörffel W; Nessler G; Kühl J; Riehm H
Leukemia; 1998 May; 12(5):645-51. PubMed ID: 9593260
[TBL] [Abstract][Full Text] [Related]
19. Acute lymphoblastic leukemia and down syndrome: 6-mercaptopurine and methotrexate metabolites during maintenance therapy.
Østergaard A; Bohnstedt C; Grell K; Degn M; Zeller B; Taskinen M; Hafsteinsdottir S; Björgvinsdóttir H; Heyman M; Hoogerbrugge P; Schmiegelow K;
Leukemia; 2021 Mar; 35(3):863-866. PubMed ID: 32623444
[No Abstract] [Full Text] [Related]
20. Neuropsychological late effects of treatment for acute leukemia in children with Down syndrome.
Roncadin C; Hitzler J; Downie A; Montour-Proulx I; Alyman C; Cairney E; Spiegler BJ
Pediatr Blood Cancer; 2015 May; 62(5):854-8. PubMed ID: 25545182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
